Skip to main content

Advertisement

SpringerLink
Log in

Exploring inhibitory potential of Curcumin against various cancer targets by in silico virtual screening

  • Published:
Interdisciplinary Sciences: Computational Life Sciences Aims and scope Submit manuscript

Abstract

Various types of cancer accounts for 10% of total death worldwide which necessitates better therapeutic strategies. Curcumin, a curcuminoid present in Curcuma longa, shown to exhibit antioxidant, anti-inflammatory and anticarcinogenic properties. Present study, we aimed to analyze inhibitory properties of curcumin towards virulent proteins for various cancers by computer aided virtual screening. Based on literature studies, twenty two receptors were selected which have critical virulent functions in various cancer. The binding efficiencies of curcumin towards selected targets were studied by molecular docking. Out of all, curcumin showed best results towards epidermal growth factor (EGF), virulent protein of gastric cancer; glutathione-S-transferase Pi gene (GST-PI), virulent protein for prostate cancer; platelet-derived growth factor alpha (PDGFA), virulent protein for mesothelioma and glioma compared with their natural ligands. The calculated binding energies of their docked conformations with curcumin found to be −7.59 kcal/mol, −7.98 kcal/mol and −7.93 kcal/mol respectively. Further, a comparative study was performed to screen binding efficiency of curcumin with two conventional antitumor agents, litreol and triterpene. Docking studies revealed that calculated binding energies of docked complex of litreol and EGF, GST-PI and PDGFA were found to be −5.08 kcal/mol, −3.69 kcal/mol and −1.86 kcal/mol respectively. The calculated binding energies of triterpene with EGF and PDGFA were found to be −4.02 kcal/mol and −3.11 kcal/mol respectively, whereas GST-PI showed +6.07 kcal/mol, indicate poor binding. The predicted pharmacological features of curcumin found to be better than litreol and triterpene. Our study concluded that curcumin has better interacting properties towards these cancer targets than their normal ligands and conventional antitumor agents. Our data pave insight for designing of curcumin as novel inhibitors against various types of cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Aggarwal, B., Sundaram, C., Malani. N., Ichikawa. H. 2007. Curcumin: The Indian solid gold. Adv Exp Med Biol 595, 1–75.

    Article  PubMed  Google Scholar 

  2. Aggarwal, S., Takada, Y., Singh, S., Myers, J.N., Aggarwal B. 2004. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-kB signaling. Int J Cancer 111, 679–692.

    Article  CAS  PubMed  Google Scholar 

  3. Aleksandrov, A., Simonson, T. 2010. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. J Biol Chem 285, 13807–13815.

    Article  CAS  PubMed  Google Scholar 

  4. Ammon, H.P., Wahl, M.A. 1991. Pharmacology of Curcuma longa. Planta Med 57, 1–7.

    Article  CAS  PubMed  Google Scholar 

  5. Anand, P., Thomas, S.G., Kunnumakkara, A.B., Sundaram, C., Harikumar, K.B., Sung, B., Tharakan, S.T., Misra, K., Priyadarsini, I.K., Rajasekharan, K.N., Aggarwal, B.B. 2008. Biological activities of curcumin and its analogues (Congeners) made by man and mother nature. Biochem Pharmacol 76, 1590–1611.

    Article  CAS  PubMed  Google Scholar 

  6. Balius, T.E., Rizzo, R.C. 2009. Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry 48, 8435–8448.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., Shindyalov, I.N., Bourne, P.E. 2000. The Protein Data Bank. Nucl Acid Res 28, 235–242.

    Article  CAS  Google Scholar 

  8. Bustanji, Y., Taha, M.O., Almasri, I.M., Al-Ghussein, M.A., Mohammad, M.K., Alkhatib, H.S. 2009. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation. J Enzyme Inhib Med Chem 24, 771–778.

    Article  CAS  PubMed  Google Scholar 

  9. Byron, S.A., Pollock, P.M. 2009. FGFR2 as a molecular target in endometrial cancer. Future Oncol 5, 27–32.

    Article  CAS  PubMed  Google Scholar 

  10. Chattopadhyay, I., Biswas, K., Bandyopadhyay, U., Banerjee, R.K. 2004. Turmeric and curcumin biological actions and medicinal applications. Curr Sci 87, 44–50.

    CAS  Google Scholar 

  11. Chène, P. 2003. Inhibiting the p53-MDM2 interaction: An important target for cancer therapy. Nat Rev Cancer 3, 102–109.

    Article  PubMed  Google Scholar 

  12. Chinnam, M., Goodrich, D.W. 2011. RB1, development, and cancer. Curr Top Dev Biol 94, 129–169.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Cicenas, J. 2008. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 23, 1–9.

    CAS  PubMed  Google Scholar 

  14. Curran, J.E., Weinstein, S.R., Griffiths, L.R. 2002. Polymorphic variants of NFKB1 and its inhibitory protein NFKBIA, and their involvement in sporadic breast cancer. Cancer Lett 188, 103–107.

    Article  CAS  PubMed  Google Scholar 

  15. Dikshit, R., Gupta, P.C., Ramasundarahettige, C., Gajalakshmi, V., Aleksandrowicz, L., Badwe, R., Kumar, R., Roy, S., Suraweera, W., Bray, F., Mallath, M., Singh, P.K., Sinha, D.N., Shet, A.S., Gelband, H., Jha, P. 2007. Cancer mortality in India: A nationally representative survey. Lancet 379, 1807–1816.

    Article  Google Scholar 

  16. Elattar, T.M., Virji, A.S. 2000. The inhibitory effect of curcumin, genistein, quercetin and cisplatin on the growth of oral cancer cells in-vitro. Anticancer Res 20, 1733–1738.

    CAS  PubMed  Google Scholar 

  17. Elumalai, M., Muthaiah, R., Alf, M.A. 2012. Identification of curcumin targets in neuroinflammatory pathways: Molecular docking scores with GSK-3beta, p38 MAPK, COX, ICE and TACE enzymes. Acta Pol Pharm 69, 237–245.

    CAS  PubMed  Google Scholar 

  18. Greten, F.R, Wagner, M., Weber, C.K., Zechner, U., Adler, G., Schmid, R.M. 2001. TGF alpha transgenic mice. A model of pancreatic cancer development. Pancreatology 1, 363–368.

    CAS  Google Scholar 

  19. Heidegger, I., Pircher, A., Klocker, H., Massoner, P. 2011. Targeting the insulin-like growth factor network in cancer therapy. Cancer Biol Ther 11, 701–707.

    Article  CAS  PubMed  Google Scholar 

  20. Heinlein, C.A., Chang, C. 2004. Androgen receptor in prostate cancer. Endocr Rev 25, 276–308.

    Article  CAS  PubMed  Google Scholar 

  21. Hewish, M., Chau, I., Cunningham, D. 2009. Insulinlike growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine. Recent Pat Anticancer Drug Discov 4, 54–72.

    Article  CAS  PubMed  Google Scholar 

  22. Hockenbery, D.M. 1994. bcl-2 in cancer, development and apoptosis. J Cell Sci Suppl 18, 51–55.

    Article  CAS  PubMed  Google Scholar 

  23. Howe, L.R., Subbaramaiah, K., Patel, J., Masferrer, J.L., Deora, A., Hudis, C., Thaler, H.T., Muller, W.J., Du, B., Brown, A.M., Dannenberg, A.J. 2002. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res 62, 5405–5407.

    CAS  PubMed  Google Scholar 

  24. Jalili, A., Wagner, C., Pashenkov, M., Pathria, G., Mertz, K.D., Widlund, H.R., Lupien, M., Brunet, J.P., Golub, T.R, Stingl, G., Fisher, D.E., Ramaswamy, S., Wagner, S.N. 2012. Dual suppression of the cyclindependent kinase inhibitors CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst 104, 1673–1679.

    Article  CAS  PubMed  Google Scholar 

  25. Jurenka, J.S. 2009. Anti-inflammatory properties of curcumin, a major constituent of Curcima longa: A review of preclinical and clinical research. Altern Med Rev 14, 141–153.

    PubMed  Google Scholar 

  26. Kanehisa, M., Goto, S. 2000. KEGG: Kyoto encyclopedia of genes and genomes. Nucl Acid Res 28, 27–30.

    Article  CAS  Google Scholar 

  27. Li, J., Kleeff, J., Giese, N., Büchler, M.W., Korc, M., Friess, H. 2004. Gefitinib (‘Iressa’, ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol 25, 203–210.

    CAS  PubMed  Google Scholar 

  28. Lin, Y.G., Kunnumakkara, A.B., Nair, A., Merritt, W.M., Han, L.Y., Armaiz-Pena, G.N., Kamat, A.A., Spannuth, W.A., Gershenson, D.M., Lutgendorf, S.K., Aggarwal, B.B., Sood, A.K. 2007. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res 13, 3423–3430.

    Article  CAS  PubMed  Google Scholar 

  29. Liu, K.W., Hu, B., Cheng, S.Y. 2011. Platelet-derived growth factor receptor alpha in glioma: A bad seed. Chin J Cancer 30, 590–602.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Liu, Z., Liu, L., Li, M., Wang, Z., Feng, L., Zhang, Q., Cheng, S., Lu, S. 2011. Epidermal growth factor receptor mutation in gastric cancer. Pathology 43, 234–238.

    Article  CAS  PubMed  Google Scholar 

  31. LoTempio, M.M., Veena, M.S., Steele, H.L., Ramamurthy, B., Ramalingam, T.S., Cohen, A.N., Chakrabarti, R., Srivatsan, E.S., Wang, M.B. 2005. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin Cancer Res 11, 6994–7002.

    Article  CAS  PubMed  Google Scholar 

  32. Machin, P., Catasus, L., Pons, C., Muñoz, J., Matias-Guiu, X., Prat, J. 2002. CTNNB1 mutations and betacatenin expression in endometrial carcinomas. Hum Pathol 33, 206–212.

    Article  CAS  PubMed  Google Scholar 

  33. Maekawa, T., Maniwa, Y., Doi, T., Nishio, W., Yoshimura, M., Ohbayashi, C., Hayashi, Y., Okita, Y. 2009. Expression and localization of FOXO1 in nonsmall cell lung cancer. Oncol Rep 22, 57–64.

    CAS  PubMed  Google Scholar 

  34. Malavaki, C.J, Roussidis, A.E., Gialeli, C., Kletsas, D., Tsegenidis, T., Theocharis, A.D., Tzanakakis, G.N., Karamanos, N.K. 2013. Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells. FEBS J 280, 2477–2489.

    Article  CAS  PubMed  Google Scholar 

  35. Medina, P.J., Goodin, S. 2008. Lapatinib: A dual inhibitor of human epidermal growth factor receptor tyrosine kinases. Clin Ther 30, 1426–1447.

    Article  CAS  PubMed  Google Scholar 

  36. Mendelsohn, J., Baselga, J. 2006. Epidermal growth factor receptor targeting in cancer. Semin Oncol 33, 369–385.

    Article  CAS  PubMed  Google Scholar 

  37. Mohandas, K.M., Desai, D.C. 1990. Epidemiology of digestive tract cancers in India. Indian J Gastroenterol 18, 118–121.

    Google Scholar 

  38. Morris, G.M., Goodsell, D.S., Huey, R., Olson, A.J. 1996. Distributed automated docking of flexible ligands to proteins: Parallel applications of AutoDock 2.4. J Comput Aided Mol Des 10, 293–304.

    Article  CAS  PubMed  Google Scholar 

  39. Mukhopadhyay, A., Bueso-Ramos, C., Chatterjee, D., Pantazis, P., Aggarwal, B.B. 2001. Curcumin down regulates cell survival mechanisms in human prostate cancer cell lines. Oncogene 20, 7597–609.

    Article  CAS  PubMed  Google Scholar 

  40. Re, A., Aiello, A., Nanni, S., Grasselli, A., Benvenuti, V., Pantisano, V., Strigari, L., Colussi, C., Ciccone, S., Mazzetti, A.P., Pierconti, F., Pinto, F., Bassi, P., Gallucci, M., Sentinelli, S., Trimarchi, F., Bacchetti, S., Pontecorvi, A., Lo Bello, M., Farsetti, A. 2011. Silencing of GST-PI, a prostate cancer prognostic gene, by the estrogen receptor-β and endothelial nitric oxide synthase complex. Mol Endocrinol 25, 2003–2016.

    Article  CAS  PubMed  Google Scholar 

  41. Russoa, A., Cardile, V., Ioannes, A.D., Garbarino, J. 2009. Effect of litreol on the viability of human cancer cells. Chemico-Biological Interactions 179, 178–184.

    Article  Google Scholar 

  42. Sauter, G., Moch, H., Moore, D., Carroll, P., Kerschmann, R., Chew, K., Mihatsch, M.J., Gudat, F., Waldman, F. 1993. Heterogeneity of erbB-2 gene amplification in bladder cancer. Cancer Res 53(10 Suppl), 2199–2203.

    CAS  PubMed  Google Scholar 

  43. Seal, A., Aykkal, R., Babu, R.O., Ghosh, M. 2011. Docking study of HIV-1 reverse transcriptase with phytochemicals. Bioinformation 5, 430–439.

    Article  PubMed Central  PubMed  Google Scholar 

  44. Siwak, D.R., Shishodia, S., Aggarwal, B.B., Kuzrock, R. 2005. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogenactivated/ extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 104, 879–890.

    Article  CAS  PubMed  Google Scholar 

  45. Skariyachan, S., Mahajanakatti, A.B., Sharma, N., Karanth, S., Rao, S., Rajeswari, N. 2012. Structure based virtual screening of novelinhibitors against multidrug resistant superbugs. Bioinformation 8, 420–425.

    Article  PubMed Central  PubMed  Google Scholar 

  46. Stoscheck, C.M., King, L.E. Jr. 1986. Role of epidermal growth factor in carcinogenesis. Cancer Res 46, 1030–1037.

    CAS  PubMed  Google Scholar 

  47. Strüh, C.M., Jäger, S., Schempp, C.M., Scheffler, A., Martin, S.F. 2012. A novel triterpene extract from mistletoe induces rapid apoptosis in murine B16.F10 melanoma cells. Phytother Res 26, 1507–1512.

    PubMed  Google Scholar 

  48. Takano, Y., Takenaka, H., Kato, Y., Masuda, M., Mikami, T., Saegusa, M., Okayasu, I. 1999. Cyclin D1 overexpression in invasive breast cancers: Correlation with cyclin-dependent kinase 4 and oestrogen receptor over expression and lack of correlation with mitotic activity. J Cancer Res Clin Oncol 125, 505–512.

    Article  CAS  PubMed  Google Scholar 

  49. Wang, D., Veena, M.S., Stevenson, K., Tang, C., Ho, B., Suh, J.D., Duarte, V.M., Faull, K.F., Mehta, K., Srivatsan, E.S., Wang M.B. 2008. Liposomeencapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin Cancer Res 14, 6228–6236.

    Article  CAS  PubMed  Google Scholar 

  50. Wang, Y., Xiao, J., Suzek, T.O., Zhang, J., Wang, J., Zhou, Z. 2012. PubChem’s BioAssay Database. Nucl Acid Res 40, D400–412.

    Article  CAS  Google Scholar 

  51. Wilken, R., Veena, M.S., Wang, M.B., Srivatsan, E.S. 2011. Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma. Mol Cancer 10, 12.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  52. Xu, G., Chu, Y., Jiang, N., Yang, J., Li, F. 2012. The Three Dimensional Quantitative Structure Activity Relationships (3D-QSAR) and docking studies of curcumin derivatives as androgen receptor antagonists. Int J Mol Sci 13, 6138–6155.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  53. Xu, Y.Y., Cao, Y., Ma, H., Li, H.Q., Ao, G.Z. 2013. Design, synthesis and molecular docking of alpha, beta-unsaturated cyclohexanone analogous of curcumin as potent EGFR inhibitors with antiproliferative activity. Bioorg Med Chem 21, 388–394.

    Article  CAS  PubMed  Google Scholar 

  54. Yokomizo, A., Kohno, K., Wada, M., Ono, M., Morrow, C.S., Cowan, K.H., Kuwano, M. 1995. Markedly decreased expression of glutathione S-transferase pi gene in human cancer cell lines resistant to buthionine sulfoximine, an inhibitor of cellular glutathione synthesis. J Biol Chem 270, 19451–19457.

    Article  CAS  PubMed  Google Scholar 

  55. Yuan, M., Luo, M., Song, Y., Xu, Q., Wang, X., Cao, Y., Bu, X., Ren, Y., Hu, X. 2011. Identification of curcumin derivatives as human glyoxalase I inhibitors: A combination of biological evaluation, molecular docking, 3D-QSAR and molecular dynamics simulation studies. Bioorg Med Chem 19, 1189–1196.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. R & D Center, Department of Biotechnology, Dayananda Sagar College of Engineering, Bangalore, 560078, Karnataka, India

    Arpitha Badarinath Mahajanakatti, Narasimha Sharma & Sinosh Skariyachan

  2. Department of Bioinformatics, PES Institute of Technology, Bangalore, 560085, Karnataka, India

    Geetha Murthy

  3. Infosys, Bangalore, 560100, Karnataka, India

    Narasimha Sharma

Authors
  1. Arpitha Badarinath Mahajanakatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Geetha Murthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Narasimha Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sinosh Skariyachan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sinosh Skariyachan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mahajanakatti, A.B., Murthy, G., Sharma, N. et al. Exploring inhibitory potential of Curcumin against various cancer targets by in silico virtual screening. Interdiscip Sci Comput Life Sci 6, 13–24 (2014). https://doi.org/10.1007/s12539-014-0170-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12539-014-0170-8

Key words

Search

Navigation